FCGR3A and neoplasm: The bispecific antibody AFM13 (CD30/CD16A) is an innovative intrinsic immune cell agonist, which activates innate immunity by specifically binding to CD30 on the surface of tumor cells and CD16A on the surface of intrinsic immune cells such as NK cells to exert antibody-dependent cell-mediated cytotoxicity (ADCC) (98, 99).